<code id='210A1BAC82'></code><style id='210A1BAC82'></style>

<acronym id='210A1BAC82'></acronym>

<center id='210A1BAC82'><center id='210A1BAC82'><tfoot id='210A1BAC82'></tfoot></center><abbr id='210A1BAC82'><dir id='210A1BAC82'><tfoot id='210A1BAC82'></tfoot><noframes id='210A1BAC82'>

<optgroup id='210A1BAC82'><strike id='210A1BAC82'><sup id='210A1BAC82'></sup></strike><code id='210A1BAC82'></code></optgroup>

<b id='210A1BAC82'><label id='210A1BAC82'><select id='210A1BAC82'><dt id='210A1BAC82'><span id='210A1BAC82'></span></dt></select></label></b><u id='210A1BAC82'></u>

~~<i id='210A1BAC82'><strike id='210A1BAC82'><tt id='210A1BAC82'><pre id='210A1BAC82'></pre></tt></strike></i>~~

天下快看面丨宣泰医药：西格列汀两甲单胍缓释片患上到药品注册证书

人参与 | 时间：2025-05-29 07:17:58

(质料图)

宣泰医药(688247)6月13日早间报告布告，天下公司背国家药监局报告的面丨西格列汀两甲单胍缓释片产物已经患上到正式允许。西格列汀两甲单胍缓释片开用于正正在收受西格列汀战两甲单胍缓释片散漫治疗的宣泰西格成人2型糖尿病患者。

医药药品

医药药品顶: 85157踩: 11

评论专区

相关文章